Cyclo3pss Corporation (CYPS) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerCyclo3pss Corporation (CYPS) trades at $0.0001. Cyclo3pss Corporation, founded in 1927, historically specialized in ozone food processing products, commercial laundry systems, and R&D for sterilization technologies. Sector: Healthcare.
Price as of · Last analyzed: Jun 14, 2026Analyst Coverage for CYPS: CYPS does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Cyclo3pss Corporation (CYPS) Healthcare & Pipeline Overview
Cyclo3pss Corporation, founded in 1927, historically specialized in ozone food processing products, commercial laundry systems, and R&D for sterilization technologies. Based in Salt Lake City, Utah, the company suspended all operations in July 2002 due to an inability to secure necessary financing, marking its current dormant status within the Healthcare sector.
What Is the Investment Thesis for CYPS?
The investment thesis for Cyclo3pss Corporation (CYPS) is fundamentally shaped by its current operational status. The company, which historically engaged in ozone food processing products, commercial laundry systems, and sterilization R&D, formally suspended all operations in July 2002. This suspension was a direct consequence of an inability to secure necessary financing and attract willing investors. As of the current date, there is no indication from the provided data that operations have resumed or are planned to resume. Financially, CYPS exhibits a market capitalization of $0.00 billion and a free cash flow of $-0.00 billion, reflecting its dormant state. The reported profit margin of -232.3% and a gross margin of 36.6% are historical metrics that predate or immediately followed the operational suspension, highlighting significant financial challenges. With a beta of 21.99, the stock historically demonstrated extreme volatility, though this metric's relevance is diminished given the lack of active trading and operations. Value drivers are currently non-existent, as the company generates no revenue and has no active business. Any potential for future value would hinge entirely on an unforeseen and unannounced revival of operations, which is not supported by current information.
Based on FMP financials and quantitative analysis
CYPS Key Highlights
Market Capitalization: Reported at $0.00 billion, reflecting the company's dormant status and minimal market valuation.
- Profit Margin: A historical profit margin of -232.3% indicates significant unprofitability during its operational period or immediately prior to suspension.
- Gross Margin: A gross margin of 36.6% suggests that while the company could generate revenue above direct costs, operational expenses significantly outweighed this.
- Free Cash Flow: Recorded at $-0.00 billion, consistent with a company that has suspended all operations and is not generating cash.
- Operational Status: All company operations were suspended in July 2002 due to an inability to secure necessary financing, rendering it currently inactive.
Who Are CYPS's Competitors?
CYPS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| INBS Intelligent Bio Solutions Inc. | $1.66 | 0.00% | $5.51M | — |
| NDRA ENDRA Life Sciences Inc. | $6.06 | +3.06% | $7.70M | 32 5-pillar |
| ADVB Advanced Biomed Inc. Common Stock | $6.73 | -2.60% | $9.30M | 62 5-pillar |
| BNGO Bionano Genomics, Inc. | $1.41 | -4.73% | $16.2M | — |
| BNR Burning Rock Biotech Limited | $16.50 | +1.54% | $17.4M | — |
| MDXH MDxHealth SA | $0.57 | -0.90% | $29.3M | — |
| QUCY QUCY | $1.34 | -0.74% | $30.5M | — |
| STRR Star Equity Holdings, Inc. | $9.76 | -1.11% | $36.1M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CYPS's Key Strengths?
Historical expertise in ozone-based sterilization and processing technologies.
- Established R&D capabilities in consumer product disinfection.
- Long operating history since 1927, indicating foundational knowledge.
- Specialized product offerings for niche industrial applications.
What Are CYPS's Weaknesses?
Suspended all operations in July 2002 due to financial insolvency.
- Inability to secure necessary and suitable financing.
- Extremely negative profit margin (-232.3%) historically.
- Minimal employee base (4 employees) indicating limited operational capacity.
What Are the Key Risks for CYPS?
All company operations have been suspended since July 2002, leading to no active revenue generation or business activities.
- Persistent inability to secure necessary and suitable financing, which was the stated reason for operational suspension.
- Extreme historical unprofitability, evidenced by a profit margin of -232.3%, suggesting significant challenges if operations were to resume.
- Very high historical beta of 21.99, indicating extreme price volatility and speculative nature if the stock were actively traded.
- Lack of public disclosure and transparency ("Unknown" disclosure status) poses significant information risk for investors.
What Threats Does CYPS Face?
- Continued operational dormancy leading to irrelevance and potential delisting.
- Technological obsolescence of historical products and R&D if not updated.
- Intense competition from active companies in the sterilization and industrial sanitation markets.
- Inability to attract capital for any potential future restart of operations.
What Are CYPS's Competitive Advantages?
- Historical specialization in ozone-based technologies for specific industrial applications.
- Proprietary knowledge and intellectual property developed through its R&D efforts in ozone sterilization.
- Early market presence in ozone food processing and commercial laundry systems since its founding in 1927.
- Established expertise in the licensing, manufacturing, and installation of complex ozone systems.
- However, the company's operational suspension since 2002 significantly diminishes the current relevance of these historical competitive advantages.
What Does CYPS Do?
Cyclo3pss Corporation, established in 1927 and headquartered in Salt Lake City, Utah, historically operated within the Healthcare sector, specifically focusing on Medical - Diagnostics & Research. The company's primary business activities encompassed the licensing, manufacturing, sale, and installation of specialized ozone food processing products. These systems were designed to enhance food safety and preservation through advanced ozone application technologies. Beyond the food industry, Cyclo3pss also developed and marketed ozone washing and laundry sorting and counting systems tailored for commercial and institutional laundries, addressing efficiency and sanitation needs in large-scale operations. In addition to its product lines, Cyclo3pss maintained a research and development arm dedicated to exploring and advancing technologies for the sterilization and disinfection of various consumer products. This R&D focus aimed to innovate solutions for public health and hygiene, aligning with its broader mission within the healthcare domain. For decades, the company contributed to specialized industrial and commercial sanitation markets with its unique ozone-based offerings. However, a pivotal moment occurred in July 2002 when the Board of Directors made the decision to immediately suspend all company operations. This drastic measure was necessitated by a critical inability to locate willing investors and secure the essential and suitable financing required to sustain its business activities. Consequently, Cyclo3pss Corporation has remained dormant since that time, with its historical operations ceased and no active business functions reported. Its legacy remains in its past contributions to ozone technology applications in food and laundry sectors, alongside its prior R&D endeavors.
What Products and Services Does CYPS Offer?
- Licenses, manufactures, sells, and installs ozone food processing products.
- Provides ozone washing and laundry sorting and counting systems for commercial and institutional laundries.
- Engages in research and development of technologies for sterilizing and disinfecting consumer products.
- Historically focused on advanced ozone application technologies for sanitation and preservation.
- Aimed to serve the food industry and large-scale commercial laundry operations.
- Conducted R&D to innovate solutions for public health and hygiene.
- Suspended all operations in July 2002 due to financial difficulties.
How Does CYPS Make Money?
- Historically generated revenue through the sale and installation of ozone-based processing and laundry systems.
- Engaged in licensing its proprietary ozone technology to other entities.
- Invested in research and development, aiming to commercialize new sterilization and disinfection technologies.
- Focused on B2B sales to commercial and institutional clients in food and laundry sectors.
- Operations have been suspended since July 2002, indicating no active revenue generation.
What Industry Does CYPS Operate In?
Cyclo3pss Corporation historically positioned itself within the specialized segments of the Healthcare sector, specifically under Medical - Diagnostics & Research, by focusing on ozone-based technologies. Its business model addressed critical needs in food safety and commercial sanitation. The market for ozone food processing, while niche, targets the broader food industry's demand for effective, chemical-free sterilization and preservation methods. Similarly, ozone washing and laundry systems cater to the commercial and institutional laundry sector, which continuously seeks efficient, environmentally friendly, and cost-effective solutions for high-volume sanitation. The company's R&D efforts in consumer product sterilization also aligned with public health trends. Historically, the competitive landscape would have included other providers of industrial sterilization equipment and commercial laundry solutions, as well as companies developing alternative disinfection technologies. However, with operations suspended since July 2002, Cyclo3pss is no longer an active participant in these markets, and its historical positioning is now a matter of record rather than current market influence.
Who Are CYPS's Key Customers?
- Commercial food processing facilities requiring sterilization and preservation solutions.
- Institutional laundries, such as hospitals, hotels, and large commercial cleaning services.
- Potentially, consumers indirectly through R&D for consumer product sterilization (if commercialized).
- Historically, businesses seeking advanced ozone technology for sanitation and efficiency.
- Currently, no active customer base due to suspended operations.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
Cyclo3pss Corporation operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in Salt Lake City, US. The company is led by CEO William R. Stoddard. CYPS has traded publicly since 2010.
CYPS Financials
CYPS Latest News
No recent news available for CYPS.
CYPS Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for CYPS.
Price Targets
Wall Street price target analysis for CYPS.
CYPS MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for CYPS; grades run from A+ (80-100) to F (below 30).
Leadership: William R. Stoddard
CEO
William R. Stoddard serves as the CEO of Cyclo3pss Corporation. His leadership is noted in the context of managing the company's small team of four employees. Given the company's operational status, his role has primarily been associated with the oversight of a dormant entity rather than active business development or expansion. The limited information suggests a focus on administrative aspects during a period of non-operation for Cyclo3pss Corporation.
Track Record: Under William R. Stoddard's leadership, Cyclo3pss Corporation's Board of Directors made the decision in July 2002 to suspend all company operations. This critical strategic decision was a direct response to the company's inability to locate willing investors and secure necessary and suitable financing. His tenure has therefore been characterized by the management of a company in a state of operational dormancy. No specific achievements related to business growth, product launches, or market expansion are available in the provided data.
CYPS OTC Market Information
Cyclo3pss Corporation trades on the OTC market under the "OTC Other" tier. This designation typically applies to companies that do not meet the disclosure or financial standards of higher OTC tiers like OTCQX or OTCQB, nor the stringent requirements of major exchanges like the NYSE or NASDAQ. Companies in the "OTC Other" tier often have limited public information, may not file with the SEC, and can be considered speculative. Unlike exchanges with strict listing standards for market capitalization, financial health, and governance, "OTC Other" has minimal requirements, resulting in a wide range of company quality and transparency.
- OTC Tier: OTC Other
- Lack of public disclosure and financial transparency due to "Unknown" disclosure status.
- Extremely low liquidity and potential for no active trading, making exiting positions difficult.
- Company operations suspended since 2002, indicating no active business or revenue generation.
- High historical beta (21.99) suggests extreme price volatility if trading were to resume.
- Risk of delisting or further market tier degradation due to prolonged dormancy and lack of reporting.
- Verify the current operational status and any potential plans for reactivation (not indicated in data).
- Attempt to locate any available financial statements or disclosures, despite "Unknown" status.
- Research the background and current involvement of management, particularly William R. Stoddard.
- Assess the legal and regulatory standing of the company, including any outstanding obligations.
- Investigate historical assets or intellectual property that might hold residual value.
- Examine any recent trading activity or market maker interest, if discernible.
- Understand the implications of the $0.00 billion market cap and negative financial metrics.
- Founded in 1927, indicating a long historical corporate existence.
- Clearly defined historical business activities in ozone food processing and laundry systems.
- Headquartered in Salt Lake City, Utah, providing a verifiable physical location.
- Identified CEO/Leadership (William R. Stoddard) with a stated role.
- However, the suspension of operations since 2002 and "Unknown" disclosure status significantly diminish current operational legitimacy.
What Investors Ask About Cyclo3pss Corporation (CYPS) — Healthcare
What is the current operational status of Cyclo3pss Corporation, and what led to this situation?
Cyclo3pss Corporation's current operational status is dormant. In July 2002, the company's Board of Directors made the decision to immediately suspend all operations.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Information is based solely on provided data.
- Company operations suspended in July 2002, impacting applicability of certain forward-looking analysis sections.
- Lack of detailed financial history beyond provided metrics.